Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
about
Regulating the ARNT/TACC3 Axis: Multiple Approaches to Manipulating Protein/Protein Interactions with Small MoleculesIncreasing Chemical Space Coverage by Combining Empirical and Computational Fragment ScreensVirtual and biophysical screening targeting the γ-tubulin complex--a new target for the inhibition of microtubule nucleationEmerging role of surface plasmon resonance in fragment-based drug discovery.High-throughput screening of small molecule ligands targeted to live bacteria surface.A ligand-observed mass spectrometry approach integrated into the fragment based lead discovery pipeline.Using chiral molecules as an approach to address low-druggability recognition sites.Inhibition of noroviruses by piperazine derivativesNew Frontiers in DruggabilityGenetic Approaches to Facilitate Antibacterial Drug Development.Partially Saturated Bicyclic Heteroaromatics as an sp(3) -Enriched Fragment Collection.Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases.Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.Vemurafenib in melanoma.Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD finger.Discovery of Schaeffer's acid analogues as lead structures of mycobacterium tuberculosis type II dehydroquinase using a rational drug design approach.Multi-target Fragments Display Versatile Binding Modes.Chemical fragment arrays for rapid druggability assessment.On the origins of drug polypharmacology
P2860
Q27675499-10851760-A9F0-466D-9CC2-59F1128122CCQ27683679-A593282D-BFE1-4842-ACE9-E62BA1021BE4Q28488055-DE3101A3-971E-4ED1-AB2E-3AF1494A85F2Q34049517-3945648F-66BC-4CF6-96B3-2A714FF42019Q34609088-5EAC1C44-559A-4C8B-9070-9BB4A4F82026Q35065764-D1C2AC96-A4F7-448D-9F9A-C6F5D1B5C315Q35253755-25E0CA61-7834-4015-B4D8-F57AA7158931Q35643211-1F298549-D031-464A-A620-E82E9D241D57Q35730955-03DDAFA7-4C21-4E26-BADF-282CF7466EB5Q35795582-FBB96E1C-552B-4B56-B103-626EBBD7FA77Q36123327-D1FC3FA5-7042-4FED-A920-5C0F9A4205C7Q36382655-B7A81405-B9A8-4A36-8EC3-8214E6290520Q37113973-DD0DEFCC-6E93-494F-BA1E-A541F99ADF81Q38101603-91DC28E3-8A04-47FD-80AA-727A2758A0CCQ39111904-71EE5FE8-ECA5-453F-A7E7-5C31D636CF52Q43633532-BA5AEAC8-3AAC-4F13-88F1-AECF3F5004A0Q48153519-16830E18-14B7-473E-AD38-4450C0CD4163Q52855914-24206331-3BAD-423C-BC33-6983BAD74895Q57012617-FED12039-BEAD-4D7F-B5D7-BF64CD36EDDE
P2860
Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Ligand specificity, privileged ...... from fragment-based screening.
@ast
Ligand specificity, privileged ...... from fragment-based screening.
@en
type
label
Ligand specificity, privileged ...... from fragment-based screening.
@ast
Ligand specificity, privileged ...... from fragment-based screening.
@en
prefLabel
Ligand specificity, privileged ...... from fragment-based screening.
@ast
Ligand specificity, privileged ...... from fragment-based screening.
@en
P1476
Ligand specificity, privileged ...... from fragment-based screening
@en
P2093
Sarah Barelier
P304
P356
10.1016/J.CBPA.2011.02.020
P577
2011-03-14T00:00:00Z